J&J, Bayer Xarelto expanded-use trial fails

Aug 27, 2018

Bayer and Johnson & Johnson’s push to widen the patient group for their heart drug Xarelto hit a stopping point when a trail failed to find a safe benefit for at-risk patients facing incidents of venous thromboembolism (VTE).

A major study of more than 12,000 patients, called Mariner, produced no clear evidence that the blockbuster clot prevention drug reduced the rate of dangerous blood clots among a certain group of high-risk patients after discharge from hospital.

Xarelto brought in $3.84 billion for Bayer last year. Bayer has the marketing rights for the drug outside the United States while partner J&J sells Xarelto in the U.S., with Bayer being eligible for royalties on U.S. sales of 20 to 30 percent.

Read the Reuters coverage

Want to get content like this in your inbox?  Subscribe to our eNewsletter here!